IDEXX Introduces the Catalyst Dx™ Chemistry Analyzer [Trade]
This significant upgrade to the IDEXX VetLab® Suite offers unprecedented efficiencies

Westbrook, Maine, January 18, 2008—IDEXX Laboratories, Inc. (NASDAQ:IDXX), introduces the IDEXX Catalyst Dx™ Chemistry Analyzer, bringing revolutionary efficiency, flexibility, speed, throughput and test menu breadth to the veterinary point-of-care market. This next-generation addition to the IDEXX VetLab® Suite puts complete chemistry results in veterinarians’ hands quickly and with less technician time than it takes to prepare a sample for an outside laboratory. The new analyzer will be introduced at the North American Veterinary Conference (NAVC) in January of this year. IDEXX will begin taking orders in February and first shipments are expected to begin in March.

The Catalyst Dx Analyzer continues the IDEXX tradition of offering IDEXX VetLab Suite upgrades that help veterinarians advance their practice of medicine with expanded, cutting-edge, in-house diagnostic laboratory capability. With the Catalyst Dx’s ability to run up to a Chem 22 profile in just eight minutes, veterinarians will be able to offer their clients real-time answers at the point of care. In addition, Catalyst Dx runs multiple patient samples simultaneously and provides preanesthetic panel results at a rate of 14 patients per hour. Automated features such as onboard whole blood separation and pipetting allow technicians to load samples simply and quickly, freeing them to move ahead with other pressing tasks while results are automatically generated.

With a comprehensive test menu that includes 27 different tests for blood and urine and seven preloaded CLIPs of slides, Catalyst Dx offers unprecedented convenience and complete flexibility in testing. The preloaded CLIPs are simple to use and are designed to meet the needs of preanesthetic protocols, wellness and sick patient visits, and feline, canine and equine species. Single slides can be run individually, in combination or added to CLIPs, enabling veterinarians to create the precise test panel desired for monitoring the health of specific organs, rechecking values over time and providing individualized patient care.

The Catalyst Dx Analyzer employs the same trusted IDEXX dry-slide technology used with IDEXX’s market-leading VetTest® Chemistry Analyzer, used by more veterinarians worldwide. Utilizing layers to filter out interfering substances typical in veterinary samples, dry-slide technology offers accurate results on even compromised samples.

“The Catalyst Dx will reinvent diagnostic testing in veterinary medicine. Our philosophy is to give veterinarians everything they need within minutes and with the least technician time,” says Jonathan W. Ayers, CEO of IDEXX Laboratories. “We offer solutions that provide veterinarians with complete lab results at the point of care without waiting and without sacrificing staff productivity.”

The IDEXX VetLab Suite offers a comprehensive in-house laboratory capability, covering chemistry, electrolytes, hematology, endocrinology, urinalysis, coagulation, infectious diseases and blood gases. All results are collected in a central database and printed on an integrated report for easy interpretation. While IDEXX will continue to offer, support and invest in the VetTest® analyzer, the world's leading chemistry analyzer, for the future, Catalyst Dx now provides a new higher-end chemistry analyzer alternative.

For more information, go to www.idexx.com/catalyst or call IDEXX at 1-800-355-2896.

About the IDEXX VetLab® Suite
The IDEXX VetLab® Suite is a highly integrated set of veterinary analyzers that provides fast and flexible results on a patient’s blood and urine within minutes of the pet visit. Diagnostic capabilities of the suite include clinical chemistry, electrolytes, hematology with five-part differential and reticulocytes, endocrinology, blood gases, coagulation, urinalysis and infectious diseases. The IDEXX VetLab® Station, which serves as an information system for the in-house laboratory, uses the power of SmartLink™ technology to integrate results from all the analyzers—including the new Catalyst Dx and SNAPshot Dx™ Analyzers—and IDEXX SNAP® point-of-care tests into a single comprehensive and easy-to-use patient report and stores this information in its database for easy future reference and historical results-trending capability.

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice management systems and pharmaceuticals. IDEXX products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 4,500 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements
This press release contains statements about the Company’s business that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the effectiveness of the Company’s sales and marketing activities; the Company’s ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; the impact of competition and technological change on the markets for the Company’s products; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the Company’s products and decisions regarding labeling, manufacturing and marketing products; the impact of distributor purchasing decisions on sales of the Company’s products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company’s inventories; the Company’s ability to manufacture complex biologic products; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2006 (1.5 MB), and on the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 (743 KB), in the section captioned “Risk Factors.”